Silence Therapeutics (SLN) Cash & Equivalents (2019 - 2025)
Historic Cash & Equivalents for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $102.2 million.
- Silence Therapeutics' Cash & Equivalents rose 2696.35% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 2696.35%. This contributed to the annual value of $121.3 million for FY2024, which is 7637.99% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Cash & Equivalents is $102.2 million, which was up 2696.35% from $114.2 million recorded in Q2 2025.
- Over the past 5 years, Silence Therapeutics' Cash & Equivalents peaked at $143.4 million during Q1 2024, and registered a low of $37.2 million during Q2 2023.
- In the last 5 years, Silence Therapeutics' Cash & Equivalents had a median value of $98.5 million in 2021 and averaged $91.9 million.
- Per our database at Business Quant, Silence Therapeutics' Cash & Equivalents soared by 67688.26% in 2021 and then crashed by 4272.79% in 2023.
- Silence Therapeutics' Cash & Equivalents (Quarter) stood at $99.1 million in 2021, then plummeted by 35.14% to $64.3 million in 2022, then grew by 4.3% to $67.1 million in 2023, then soared by 80.93% to $121.3 million in 2024, then dropped by 15.77% to $102.2 million in 2025.
- Its Cash & Equivalents stands at $102.2 million for Q3 2025, versus $114.2 million for Q2 2025 and $136.5 million for Q1 2025.